In a case report published in the journal Primary Care Companion to Central Nervous System Disorders, three Penn State clinicians describe a patient who experienced serotonin toxicity after combining antidepressants and anti-anxiety medications and psilocybin.
Serotonin toxicity, or serotonin syndrome, occurs when high levels of serotonin build up on the body; the condition can be fatal.
Read more
Cybin, a biotech company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of depression.
CYB003 is a next-generation psilocybin designed to provide a faster onset of action and to reduce the duration of effects, ultimately thinning the financial barrier to access of this medicine in a medical setting.
The trial’s interim data demonstrated “rapid, robust, and clinically significant reduction of depression symptoms” three weeks after a single 12mg dose of CYB003.
Read more
Keep reading for the history of the chemical imbalance theory, how a study last year tried to debunk it, and how that study is now seen to be flawed.
Read more
5 Questions for psychopharmacologist Kelan Thomas. Thomas discusses what we know — and don’t know — about potential interactions between psychedelics and SSRIs.
Read more
A new study suggests that SSRI drugs can be used safely with psilocybin to treat depression. Keep reading to learn more.
Read more
This study reports that psilocybin provides long-term relief of cancer-related anxiety and depression.
Read more